Skip to content

Effect of Galactooligosaccharides on Incidence of Atopic Manifestations in Infants

Double Blind, Randomised Study on the Effect of Prebiotics on Incidence of Atopic Manifestations in Infants

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02077088
Enrollment
120
Registered
2014-03-04
Start date
2009-06-30
Completion date
2013-04-30
Last updated
2014-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

interventional, doubleblind, randomised, pediatric, prebiotic, atopic, dermatitis, infant

Brief summary

Addition of prebiotic galactooligosaccharides to hypoallergenic starter formula would lead to decreased allergic (atopic) symptoms in nonbreastfed infants with a positive history of allergy in family

Interventions

addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides

Sponsors

Vitkovice Hospital
CollaboratorOTHER
Humana Co.Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Weeks to 8 Weeks
Healthy volunteers
No

Inclusion criteria

* nonbreastfed eutrophic infants of corresponding gestational age * presence of a positive family allergic anamnesis in parents or siblings (atopic eczema, allergic rhinitis or bronchial asthma)

Exclusion criteria

* children with serious disease, * breastfed children * children fed another formula then the ones used

Design outcomes

Primary

MeasureTime frameDescription
SCORAD (SCORing Atopic Dermatitis score) assessment of atopyat 6 months of ageobjective evaluation of atopic symptoms

Secondary

MeasureTime frame
anthropometric parameters (height, weight)at 6 months of age

Other

MeasureTime frame
incidence of febrile episodesat 6 months

Countries

Czechia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026